Halberd Corporation (OTC:HALB) researchers have been successful in in-vitro laboratory tests using buffer solution in eradicating the cancer disease antigen CTLA-4 using laser emissive energy in their latest series of tests. Halberd had been successful previously in eradicating all five cancer disease antigens.
On Thursday, HALB stock moved up 13.50% at $0.0114 on 6X its average volume. More than 5.35 million shares, compared to its average volume of 879K shares. The stock moved within a range of $0.0102 – 0.0151 after opening trade at $0.0102.
On Thursday the company announced that its researchers had been successful in removing CLTA-4, the cancer disease antigen, by deploying laser emissive energy, in the latest round of in-vitro laboratory tests. It was another major breakthrough for the company in its continued efforts to eliminate cancer antigens.
It should be noted that in the past Halberd had been successful in removing as many as five antigens in less than 10 minutes through the same process. The latest development was another feather in the cap for the company and it is going to be interesting to see if the stock can manage to come into focus among investors or not.
The Chief Technology Officer of the company Dr. Mitchell S Felder spoke about the significance of the latest breakthrough for Halberd. He noted that most cancer treatment institutions from all across the world deploy the use of anti-CLTA-4 medicines in order to treat cancer patients. Hence, it is quite clear that the latest breakthrough could well prove to be a commercially successful one for Halberd in the long run.
The Chairman, Chief Executive Officer, and President of the company William A Hartman spoke about the process as well. He noted that everyone at the company was pleased with the initial results from the lab testing.
HALB stock is trading above the 20-Day and 50-Day Moving averages of $0.0112 and $0.0108 respectively. However, the stock is trading below the 200-Day moving average of $0.0155.